Article
Oncology
Kazuaki Okamoto, Hiroaki Nozawa, Shigenobu Emoto, Koji Murono, Kazuhito Sasaki, Soichiro Ishihara
Summary: The current study aimed to investigate whether statins could prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients with colorectal cancer (CRC) receiving adjuvant CAPOX therapy. The results showed that the efficacy of statins to attenuate OIPN during adjuvant CAPOX therapy was not apparent in the current study.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Medicine, Research & Experimental
Wei Chong, Xingyu Zhu, Huicheng Ren, Chunshui Ye, Kang Xu, Zhe Wang, Shengtao Jia, Liang Shang, Leping Li, Hao Chen
Summary: This study elucidates the molecular heterogeneity of KRAS-mutant CRC and reveals new biological subtypes and therapeutic possibilities for these tumors.
Review
Oncology
Christina Teng, Jordan Cohen, Sam Egger, Prunella L. Blinman, Janette L. Vardy
Summary: Chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin is a common long-term side effect for colorectal cancer survivors, with prevalence decreasing over time. The study identified a variety of tools used in different studies to measure CIPN, highlighting the need for a standardized assessment.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Jiuna Zhang, Xiaoyu Jiang, Jie Yin, Shiying Dou, Xiaoli Xie, Ting Liu, Yijun Wang, Shuling Wang, Xue Zhou, Dongxuan Zhang, Huiqing Jiang
Summary: RNF141 plays an oncogenic role in colorectal cancer by upregulating KRAS activity, which promotes tumor growth, cell proliferation, migration, and apoptosis by interacting with KRAS to induce its activation and enrichment on the plasma membrane.
Article
Oncology
Robert B. Hines, Christopher Schoborg, Timothy Sumner, Xiang Zhu, Elizabeth A. Elgin, Shunpu Zhang
Summary: The purpose of this study was to evaluate whether preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. The results showed that no therapies reduced the rate of OIPN diagnosis.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Medicine, General & Internal
Rona Yaeger, Jared Weiss, Meredith S. Pelster, Alexander Spira, Minal Barve, Sai-Hong Ou, Ticiana A. Leal, Tanios S. Bekaii-Saab, Cloud P. Paweletz, Grace A. Heavey, James G. Christensen, Karen Velastegui, Thian Kheoh, Hirak Der-Torossian, Samuel J. Klempner
Summary: In this study, the researchers investigated the clinical efficacy of adagrasib in combination with cetuximab for heavily pretreated patients with metastatic colorectal cancer harboring mutant KRAS G12C. The results showed that the overall response rate was 19% in the adagrasib monotherapy group, with a median progression-free survival of 5.6 months, and 46% in the combination therapy group, with a median progression-free survival of 6.9 months. Both groups experienced reversible adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Shafia Rahman, Shimon Garrel, Michael Gerber, Radhashree Maitra, Sanjay Goel
Summary: Colorectal cancer is a common cancer in the United States, and approximately 45% of patients with metastatic colorectal cancer have KRAS mutations, requiring a more personalized treatment approach for these patients.
Article
Chemistry, Multidisciplinary
Li Song, Yu Hao, Chunjie Wang, Yikai Han, Yujie Zhu, Liangzhu Feng, Liyan Miao, Zhuang Liu
Summary: A liposomal nanomedicine that modulates the tumor microenvironment has been developed to enhance cancer immunotherapy. By encapsulating metformin and an oxaliplatin prodrug in liposomes, this nanomedicine reduces tumor hypoxia and induces immunogenic cell death, effectively suppressing tumor growth and reversing immunosuppression.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Pharmacology & Pharmacy
Nicolas Kerckhove, Marie Selvy, Celine Lambert, Coralie Gonneau, Gabrielle Feydel, Caroline Petorin, Agnes Vimal-Baguet, Sergey Melnikov, Sharif Kullab, Mohamed Hebbar, Olivier Bouche, Florian Slimano, Vincent Bourgeois, Valerie Lebrun-Ly, Frederic Thuillier, Thibault Mazard, David Tavan, Kheir Eddine Benmammar, Brigitte Monange, Mohamed Ramdani, Denis Pere-Verge, Floriane Huet-Penz, Ahmed Bedjaoui, Florent Genty, Cecile Leyronnas, Jerome Busserolles, Sophie Trevis, Vincent Pinon, Denis Pezet, David Balayssac
Summary: The study identified three clusters of colorectal cancer patients with oxaliplatin-related CIPN, characterized by differences in CIPN severity and neuropathic pain. Anxiety, depressive disorders, and alterations in HRQOL were lower in cluster 1 compared to clusters 2 and 3, but not significantly different between clusters 2 and 3. This suggests that CIPN patients are not a homogeneous group, and CIPN severity is associated with psychological distress and HRQOL decline. Further research is needed to explore the relationship between clusters and CIPN management.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Food Science & Technology
Jinkyung Lee, Chan Ho Jang, Yoonsu Kim, Jisun Oh, Jong-Sang Kim
Summary: This study examined the ability of quercetin to sensitize colorectal cancer cells to oxaliplatin by inhibiting glutathione reductase activity. The combination of quercetin and oxaliplatin was found to synergistically inhibit glutathione reductase activity, reduce cell viability, and increase reactive oxygen species production. Addition of sulforaphane further enhanced the anti-cancer efficacy of this combination therapy in a mouse model.
Article
Oncology
Jeeshan Jiffry, Thongthai Thavornwatanayong, Devika Rao, Elisha J. Fogel, Durvanand Saytoo, Rishika Nahata, Hillary Guzik, Imran Chaudhary, Titto Augustine, Sanjay Goel, Radhashree Maitra
Summary: The study revealed that Pelareorep can enhance its propagation and oncolytic effect in colorectal cancer cells by regulating autophagy-related genes and proteins.
CLINICAL CANCER RESEARCH
(2021)
Article
Cell Biology
Sha Zhou, Jianhong Peng, Liuniu Xiao, Caixia Zhou, Yujing Fang, Qingjian Ou, Jiayi Qin, Mengzhong Liu, Zhizhong Pan, Zhenlin Hou
Summary: TRIM25 is identified as an epigenetic regulator of oxaliplatin resistance in colorectal cancer patients, affecting disease-free survival and recurrence rates. Its overexpression promotes stem cell properties in CRC cells and resistance to chemotherapy. Targeting TRIM25 may be a potential strategy for managing OXA resistance in clinical practice.
CELL DEATH & DISEASE
(2021)
Article
Multidisciplinary Sciences
Qiming Zhou, Yao Peng, Fenfen Ji, Huarong Chen, Wei Kang, Lam-Shing Chan, Hongyan Gou, Yufeng Lin, Pingmei Huang, Danyu Chen, Qinyao Wei, Hao Su, Cong Liang, Xiang Zhang, Jun Yu, Chi Chun Wong
Summary: SLC25A22 knockout reverts KRAS-mediated immunosuppression in CRC models by suppressing CXCL1 production and impairing MDSC recruitment. Mechanistically, SLC25A22 promotes asparagine-mediated SRC phosphorylation, which drives CXCL1 transcription and MDSC infiltration. Targeting SLC25A22 in combination with anti-PD1 therapy shows promising results in inhibiting MDSC and activating CD8(+) T cells to suppress KRAS-mutant CRC growth.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, General & Internal
Ellen F. Tyler, Charles N. J. McGhee, Benjamin Lawrence, Geoffrey D. Braatvedt, Joseph L. Mankowski, Jonathan D. Oakley, Sargun Sethi, Stuti L. Misra
Summary: This study aimed to observe corneal nerve microstructure and sensitivity changes in patients receiving oxaliplatin chemotherapy, as well as peripheral neuropathy, and to determine their association with corneal parameters at different stages of treatment. The results showed that corneal changes detected on confocal microscopy have a moderate association with peripheral neuropathy, indicating their potential to identify the development of oxaliplatin-induced peripheral neuropathy.
JOURNAL OF CLINICAL MEDICINE
(2022)